

Experimental Therapeutics *Ad Hoc* Subcommittee of the NCAB

Ned Sharpless, M.D.

September 1, 2020

Charge

- To help the National Cancer Institute identify high-priority research opportunities in the area of experimental therapeutics.
- Identify areas where:
 - The NCI portfolio should be increased or changed
 - The special capabilities of the NCI would be especially helpful (as opposed to those areas better addressed by Industry)
 - Ability to work with other parts of USG
 - Ability to fund projects without regard to market size
 - Ability to convene stakeholders
 - There is potential to provide meaningful benefit for patients
- Based on initial discussion, the Subcommittee could choose a single specific area for specific, focused consideration

What could the subcommittee do?*

- Ask NCI for an analysis of a certain topic (e.g. our portfolio of RPGs that support PROTACs).
- Ask the NCI to empanel a working group to the Subcommittee with *ad hoc* membership to address a specific topic (e.g. novel forms of cellular immunotherapy).
- Advise NCI on the need for additional emphasis on a specific scientific area or the creation of new NCI infrastructure (e.g. a FNLCR program)

**Some of these would require NCAB approval.*

Examples

- Novel Medicinal Chemistry
 - AI-based drug discovery, natural products, PROTACs, etc.
- Cellular Immunotherapy and Vector Production
- Other complex biologics (gene editing, AAV, etc)
- The “Bespoke” Medicines Problem (e.g. Neoantigen vaccines)
- Precision Prevention